PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are require

Substitute (A) orm 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 1 of 4

ed to respond to a collection of intorn	nation unless it contains a valid OMB cartiol number
Con	nplete if Known
Application Number	09/825,012
Filing Date	April 3, 2001
First Named Inventor	Robert YOUNG
Group Art Unit	1642
Examiner Name	Canella, K.
Attorney Docket Number	43191/256808 (16210)

Kind Code ² Name of Patentee or Applicant Cited Document Relevant F					Ų	U.S. PATENT DOCUMENT	S		2
Examiner Initials No. Number (if known) of Cited Document MM-DD-YYYY Fig.			U.S. P	Patent Docume	int			Pages, Columns, Lines, Where	
Mi 1 5,955,073 Rybak et al. 09-21-1999			Number					Relevant Passages or Relevant Figures Appear	ant
	KAU	1	5,955,073			Rybak et al.	09-21-1999		
FOREIGN PATENT DOCUMENTS					FO	REIGN PATENT DOCUME	NTS		
Framiner Foreign Patent Document Date of Publication of Pages, C	Examiner	0:1-	Foreig	ign Patent Doc	ument		Date of Publication of	Pages, Columns, Lines, Where	
	i	No.1	Office ³ N	Number ⁴	(if known)	Applicant of Cited Document	MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	

	T	[Foreign Patent Do			Date of Publication of	Pages, Columns, Lines,	
Examiner Initials	Cite No. ¹	Office ³	Number⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ⁶
KAU	2	EP	0 239 400 A					<u>'</u>
	3	EP	0 302 473 A					
	4	EP	0 369 816 A					\perp
	5	EP	0 781 845 A					
	6	WO	88/05054					
	7 ′	WO	88/07378					\perp
	8	WO	88/09344					
	9	wo	89/07268					
	10	WO	90/05142		1 - Feb. 1			_
	11	WO	90/12319		-51			
	12	WO	91/07500		<u> </u>			
	13	WO	91/11201		·			
	14	WO	91/16069					
	15	WO	92/04380]
	16	WO	94/11508					
	17	WO	94/15644	/				
V	18	UK	2,289,679 A					

Examiner Signature	Harin (J. i	Janella	Date Considered	10	/17/03

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
d to a collection of information unless it contains a valid OMB of trol number

der the Paperwork Reduction Act of 1995, no persons are required

JAN 2 3 2003

Company to hear INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

2 of 4 Sheet

Cor	nplete if Known
Application Number	09/825,012
Filing Date	April 3, 2001
First Named Inventor	Robert YOUNG
Group Art Unit	1642
Examiner Name	Canella, K.
Attorney Docket Number	43191/256808 (16210)

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	2
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	19	J. ARKLIE et al., "Differentiation Antigens Expressed by Epithelial Cells in the Lactating Breast are Also Detectable in Breast	
KAC		Cancer", Int. J. Cancer, 28, 23-29 (1981).	
	20	K. D. BAGSHAWE, "Antibody Directed Enzymes Revive Anti-Cancer Prodrugs Concept", Br. J. Cancer, 56, 531-532 (1987).	
	21	K.D. BAGSHAWE et al., "A Cytotoxic Agent can be Generated Selectively at Cancer Sites", Br. J. Cancer, 58, 700-703 (1988).	
	22	Marc BETTER et al., "Escherichia coli Secretion of an Active Chimeric Antibody Fragment", Science 240, 1041 (May 20 1988).	
	23	Robert E. BIRD et al., "Single-Chain Antigen-Binding Proteins", Science 242, 423 (October 21 1988).	
	24	Mark I. COCKETT et al., "The Use of Engineered E1A Genes to Transactive the hCMV-MIE Promoter in Permanent CHO Cell	
		Lines", Nucleic Acids Research, Vol. 19, No. 2, 319-325 (1990).	
	25	Sandra GENDLER et al., "A Highly Immunogenic Region of a Human Polymorphic Epithelial Mucin Expressed by Carcinomas is Made up of Tandem Repeats", J. Biol. Chem, 236, 12820-12823 (1988).	
	26	Sandra J. GENDLER et al., "Molecular Cloning and Expression of Human Tumor-Associated Polymorphic Epithelial Mucin", J. Biol. Chem., 265, 15286-93 (1990).	
	27	D. J. HNATOWICH et al., "Patient Biodistribution of Intraperitoneally Administered Yttrium-90-Labeled Antibody", J. Nucl. Med., 29, 1428-1434 (1988).	
	28	Richard C. HUBBARD, M.D. et al., "A Preliminary Study of Aerosolized Recombinant Human Deoxyribonuclease I in the Treatment of Cystic Fibrosis", New Eng. J. Med., 326, 812-815 (1992).	
	29	James S. HUSTON et al., "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in <i>Escherichia coli</i> ", Proc. Natl. Acad. Sci. USA, 85, 5879 (1988).	
	30	Peter T. JONES et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse",	
		Nature, 321, 522-525 (1986).	
	31	H. P. KALOFONOS et al., "Imaging of Tumor in Patients with Indium-111-Labeled Biotin and Streptavidin-Conjugated	
\downarrow		Antibodies: Preliminary Communication, J. Nucl. Med., 31, 1791-1796 (1990).	

Examiner Signature	Haren	4.	Canella	Date Considered	10/17/03
-----------------------	-------	----	---------	--------------------	----------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0641-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control of

orm 1449/A/PTO

JAN 2 3 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 3 of 4

Co	mplete if Known
Application Number	09/825,012
Filing Date	April 3, 2001
First Named Inventor	Robert YOUNG
Group Art Unit	1642
Examiner Name	Canella, K.
Attorney Docket Number	43191/256808 (16210)

			_~
		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	- 0
xaminer Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	32	H. LINARDOU et al., "Deoxyribonuclease I (Dnase I) - A Novel Approach for Targeted Cancer Therapy", Cell Biophysics,	
KAL		24/25, 243-248 (1994).	
1.	33	Sherie L. MORRISON et al., "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant	
		Region Domains", Proc. Natl. Acad. Sci. USA, 81, 6851-6855 (1984).	
	34	Sherie L. MORRISON, "New Approaches to the Production of Monoclonal Antibodies", Science, 239, G28, 48, 112-113	
		(1988).	
+-	35	M. S. NEUBERGER et al. "Antibody Engineering", 8 th International Biotechnology Symposium Part 2, 792-799 (1988).	\top
	36	Michael J. O'SULLIVAN et al., "Comparison of Two Methods of Preparing Enzyme-Antibody Conjugates: Application of These	
		Conjugates for Enzyme Immunoassay", Anal. Biochem., 100, 100-108 (1979).	
	37	G. PAGANELLI et al., "Intraperitoneal Radio-Localization of Tumors Pre-Targeted by Biotinylated Monoclonal Antibodies", Int.	
		J. Cancer, 45, 1184-1189 (1990).	
	38	Lutz RIECHMANN et al., "Reshaping Human Antibodies for Therapy", Nature, 332, 323-327 (1988).	
	39	Susanna M. RYBAK et al., "Cytotoxic Potential of Ribonuclease and Ribonuclease Hybrid Proteins", J. Biol. Chem., 266,	
		21202 (1991).	
	40	Peter D. SENTER et al., "Anti-Tumor Effects of Antibody-Alkaline Phosphatase Conjugates in Combination with Etoposide	
		Phosphate", Proc. Natl. Acad. Sci. USA, 85, 4842 (1988).	
1	41	Steven SHAK et al., "Recombinant Human Dnase I Reduces the Viscosity of Cystic Fibrosis Sputum", Proc. Natl., Acad. Sci.	
		USA, 87, 9188-9192 (1990).	
	42	Dominick SINICROPI et al., "Colorimetric Determination of Dnase I Activity with a DNA-Methyl Green Substrate", Analyt.	
		Biochem., 222, 351-358 (1994).	
	43	Arne SKERRA et al., "Assembly of a Functional Immunoglobulin F _V Fragment in Escherichia coli", Science, 240, 1038 (1988).	1
1/			

Examiner Signature	Harin	a.	Ganella	Date Considered	10/17/03

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB consultation.

der the Paperwork Reduction Act of 1995, no persons are require

BURSHINE (RA m 1449/A/PTO

JAN 2 3 2003 8

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 4 of 4

ed to respond to a collection of infor-	nation unless it contains a valid OMB	comportunine
Cor	nplete if Known	
Application Number	09/825,012	71.
Filing Date	April 3, 2001	" 2 V
First Named Inventor	Robert YOUNG	8
Group Art Unit	1642	5 6
Examiner Name	Canella, K.	100
Attorney Docket Number	43191/256808 (16210)	m.

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	44	Joyce TAYLOR-PAPADIMITRIOU et al., "Monoclonal Antibodies to Epithelium-Specific Components of the Human Milk Fat	
KAL		Globule Membrane: Production and Reaction with Cells in Culture", Int. J. Cancer, 28, 17-21 (1981).	
1	45	Martine VERHOEYEN et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity", Science, 239, 1534-1536	
		(1988).	
	46	M.E. VERHOEYEN et al., "Reshaping Human Monoclonal Antibodies for Imaging and Therapy", Disease Markers, 9, 197-203	
	i	(1991).	•
	14	E. Sally WARD et al., "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted From	-
	47	E. Sally WARD et al., Binding Activities of a Repertoire of Single Infinitionoglobulin Variable Domains Secreted From	
		Escherichia coli ^a , Nature, 341, 544 (1989).	
	48	Greg WINTER et al., "Man-Made Antibodies", Nature, 349, 293-299 (1991).	
	49	Andrew F. WORRALL et al., "The Chemical Synthesis of a Gene Coding for Bovine Pancreatic Dnase I and Its Cloning and	
		Expression in <i>Escherichia coli</i> ", J. Biol. Chem., 265, 21889-21895 (1990).	
	50	N. Martin YOUNG et al., "Thermal Stabilization of a Single-Chain F _V Antibody Fragment by Introduction of a Disulphide Bond",	
		FEBS Lett., 377, 135-139 (1995).	
4	51	Robert J. YOUNG et al., "A Dnase I Based Immunotoxin for Tumor Therapy", Proc. Of the American Assoc. for Cancer	
$\downarrow\downarrow$		Research Annual., 41, 289 (2000).	
	52	Raymond J. OWENS et al., "The Genetic Engineering of Monoclonal Antibodies", J. Immunol. Meth., 168, 149-165 (1994).	
KAU		· ·	
			-
			1
			

	Examiner 2 Signature /	Harm o	<i>[</i>].	fámille	Date Considered	10/11/03
--	---------------------------	--------	-------------	---------	--------------------	----------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.